1. Home
  2. NAMI vs AVIR Comparison

NAMI vs AVIR Comparison

Compare NAMI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMI
  • AVIR
  • Stock Information
  • Founded
  • NAMI 2014
  • AVIR 2012
  • Country
  • NAMI China
  • AVIR United States
  • Employees
  • NAMI N/A
  • AVIR N/A
  • Industry
  • NAMI
  • AVIR Medicinal Chemicals and Botanical Products
  • Sector
  • NAMI
  • AVIR Health Care
  • Exchange
  • NAMI NYSE
  • AVIR Nasdaq
  • Market Cap
  • NAMI 286.0M
  • AVIR 247.5M
  • IPO Year
  • NAMI 2024
  • AVIR 2020
  • Fundamental
  • Price
  • NAMI $3.79
  • AVIR $3.37
  • Analyst Decision
  • NAMI
  • AVIR Hold
  • Analyst Count
  • NAMI 0
  • AVIR 1
  • Target Price
  • NAMI N/A
  • AVIR $6.88
  • AVG Volume (30 Days)
  • NAMI 104.9K
  • AVIR 528.5K
  • Earning Date
  • NAMI 02-11-2025
  • AVIR 02-26-2025
  • Dividend Yield
  • NAMI N/A
  • AVIR N/A
  • EPS Growth
  • NAMI N/A
  • AVIR N/A
  • EPS
  • NAMI 0.37
  • AVIR N/A
  • Revenue
  • NAMI $56,127,097.00
  • AVIR N/A
  • Revenue This Year
  • NAMI N/A
  • AVIR N/A
  • Revenue Next Year
  • NAMI N/A
  • AVIR N/A
  • P/E Ratio
  • NAMI $10.20
  • AVIR N/A
  • Revenue Growth
  • NAMI 64.40
  • AVIR N/A
  • 52 Week Low
  • NAMI $3.40
  • AVIR $2.75
  • 52 Week High
  • NAMI $7.75
  • AVIR $4.60
  • Technical
  • Relative Strength Index (RSI)
  • NAMI N/A
  • AVIR 55.56
  • Support Level
  • NAMI N/A
  • AVIR $3.11
  • Resistance Level
  • NAMI N/A
  • AVIR $3.60
  • Average True Range (ATR)
  • NAMI 0.00
  • AVIR 0.13
  • MACD
  • NAMI 0.00
  • AVIR 0.00
  • Stochastic Oscillator
  • NAMI 0.00
  • AVIR 53.17

About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS

Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The Company generates revenue by selling its content to hardware manufacturers in China whereby they are allowed to install the Company's digital educational content on the manufacturers' devices for sale to end users.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: